|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||10.06 - 10.26|
|52-week range||6.92 - 13.88|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Nov 2017|
|1y target est||N/A|
In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.
In March, the European Commission said it would probe whether an Israeli drugmaker used patents to stave off competition. In its investigation, Brussels will assess whether Teva “abusively blocked or delayed” market competition for Copaxone, its blockbuster multiple sclerosis drug, by strategically filing and withdrawing “divisional” patents. As such, they potentially enable drug creators to prolong the market exclusivity of products beyond the expiry of their original patents by filing new claims, which in effect extend their monopoly and block generic manufacturers.